Tests odronextamab against standard treatment in adults with aggressive B-cell lymphoma
Compares odronextamab with standard treatment in adults with previously treated aggressive lymphoma.
Plain-language title generated from the registry record
Registry title: A trial to learn how effective and safe odronextamab is compared to standard of care for adult participants with previously treated aggressive B-cell Non-Hodgkin Lymphoma.
Key facts
- Where
- Prague 10, CzechiaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with aggressive B-cell non-Hodgkin lymphoma that did not respond to, or came back after, one earlier treatment, who plan to have an autologous stem cell transplant.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- Aggressive B-cell non-Hodgkin lymphoma proven by tissue testing, with disease that can be measured on a scan (CT or MRI). The lymphoma did not respond to first treatment, or came back within 12 months or less of starting it.
- Earlier treatment
- Must have had exactly 1 earlier line of treatment that included an anti-CD20 antibody and an anthracycline. Must intend to proceed to autologous stem cell transplant (ASCT).
- Biomarker or test result
- Tumor tissue must be available to send to a central laboratory. No specific gene change is asked for in the record.
Main reasons for not taking part
- Lymphoma starting in the central nervous system, or known spread of non-primary lymphoma to it
- History of or current relevant central nervous system disease, as described in the protocol
- Another cancer, unless fully treated and cancer free for at least 3 years (some listed small cancers excepted)
- Allergy to the study drug or its ingredients
- Another serious active illness that could affect the study or put the person at risk
Read by machine on 9 November 2026.
Where in Czechia
- Fakultní Nemocnice Královské VinohradyPrague 10, CzechiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Regeneron Pharmaceuticals Inc.
- Trial code
- NCT06230224EU 2022-502783-21-00
- Record updated
- 25 May 2026
- Original description
To compare the efficacy, as defined by EFS, in participants treated with odronextamab versus participants treated with Standard of Care (SOC)Read full original descriptionShow less
A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, versus Standard of Care Therapy in Participants with Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma (OLYMPIA-4)
To compare the efficacy, as defined by EFS, in participants treated with odronextamab versus participants treated with Standard of Care (SOC)
Inclusion: Histologically proven aggressive B-NHL, as described in the protocol. Availability of tumor tissue for submission to central laboratory is required for study enrollment. Archival tumor tissue for histological assessment prior to enrollment is allowed; Have primary refractory or relapse 12 months or less (≤) from initiation of frontline therapy. Only patients who received 1 prior line of therapy containing an anti-Cluster of Differentiation 20 (CD20) antibody and anthracycline are allowed for enrollment; Have measurable disease with at least one nodal lesion with longer diameter (LDi) greater than 1.5 cm or at least one extranodal lesion with LDi greater than 1.0 cm, documented by diagnostic imaging (computed tomography [CT] or magnetic resonance imaging [MRI]); Intent to proceed to autologous stem cell transplant (ASCT), as described in the protocol; Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; Adequate hematologic and organ function; Other protocol defined inclusion criteria apply.
Exclusion: Wash-out period from prior anti-lymphoma treatments and infections, as described in the protocol; History of or current relevant CNS pathology, as described in the protocol; A malignancy other than NHL unless the participant is adequately and definitively treated and is cancer free for at least 3 years, with the exception of localized prostate cancer, cervical carcinoma in situ, breast cancer in situ, or nonmelanoma skin cancer that was definitively treated; Any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol; Allergy/hypersensitivity to study drug, or excipients; Primary central nervous system (CNS) lymphoma or known involvement by non-primary CNS NHL, as described in the protocol; Other protocol defined exclusion criteria apply.